Connects life sciences organizations with healthcare providers and patients. Provides financial messaging services to deliver sample vouchers and co-pay coupons. Now — the numbers.
This is an established company with proven profits.
Average growth of 16% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 26.7× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 92% of them.
Analysts' average target sits 41% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 16% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 44/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, OPRX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: OPRX is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
Not covered, because the filings we hold do not carry it: the revenue breakdown.